
    
      OBJECTIVES:

      Primary Objective(s):

        1. Evaluate the feasibility in terms of mortality, occurrence of acute graft versus host
           disease, and grades 3-4/4 toxicity of in vivo and in vitro Campath coupled with
           concomitantly administered nonmyeloablative fludarabine, cyclophosphamide and total body
           irradiation (TBI) followed by Human Leukocyte Antigen (HLA) 5-6/6 matched family member
           allo peripheral blood stem cell transplant (PBSCT).

        2. Evaluate the engraftment rate of HLA 5-6/6 matched family member patients who receive in
           vivo Campath followed by concomitantly administered fludarabine, cyclophosphamide and
           total body irradiation (TBI) as a conditioning regimen with Campath-treated peripheral
           blood stem cells (in vitro and in vivo exposure).

      Secondary Objective(s):

        1. Evaluate the response rate and survival of patients who receive a non-myeloablative
           conditioning regimen of in vivo Campath followed by concomitantly administered
           fludarabine, cyclophosphamide and total body irradiation (TBI) with Campath-treated
           peripheral blood stem cells.

        2. Evaluate the recovery of immune function post engraftment with this regimen.
    
  